Today: Today, 5,880 Shares of Momenta Pharmaceuticals Inc. (MNTA) Stock are sold by Craig A. Wheeler

Today, 5,880 Shares of Momenta Pharmaceuticals Inc. (MNTA) Stock are sold by Craig A. Wheeler

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) President Craig A. Wheeler sold 5,880 shares of the firm’s stock in a transaction dated Tuesday, November 22nd. The stock was sold at an average price of $13.68, for a total value of $80,438.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) opened at 14.10 on Friday. Momenta Pharmaceuticals Inc. has a one year low of $7.86 and a one year high of $18.26. The firm’s market capitalization is $972.29 million. The firm has a 50-day moving average price of $12.27 and a 200 day moving average price of $11.65.

Momenta Pharmaceuticals (NASDAQ:MNTA) last posted its quarterly earnings data on Wednesday, November 2nd. The biotechnology company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.03. Momenta Pharmaceuticals had a negative return on equity of 26.55% and a negative net margin of 93.75%. The company earned $299.14 million during the quarter, compared to analysts’ expectations of $25.68 million. During the same period last year, the firm earned ($0.44) EPS. The firm’s revenue for the quarter was up 2067.7% on a year-over-year basis. Equities analysts forecast that Momenta Pharmaceuticals Inc. will post ($1.16) earnings per share for the current fiscal year.

Several research analysts have recently issued reports on the company. Zacks Investment Research cut Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, October 5th. JPMorgan Chase & Co. dropped their target price on Momenta Pharmaceuticals from $21.00 to $15.00 and set an “overweight” rating on the stock in a report on Friday, August 5th. Aegis began coverage on Momenta Pharmaceuticals in a report on Tuesday. They set a “hold” rating and a $15.00 target price on the stock. Maxim Group reaffirmed a “sell” rating and set a $6.00 target price on shares of Momenta Pharmaceuticals in a report on Thursday, November 3rd. Finally, Barclays PLC raised Momenta Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $13.00 to $19.00 in a report on Tuesday, October 11th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $16.10.

Several hedge funds have recently bought and sold shares of MNTA. Dynamic Technology Lab Private Ltd acquired a new stake in Momenta Pharmaceuticals during the second quarter valued at approximately $109,000. PNC Financial Services Group Inc. boosted its stake in Momenta Pharmaceuticals by 2.9% in the second quarter. PNC Financial Services Group Inc. now owns 169,060 shares of the biotechnology company’s stock valued at $1,826,000 after buying an additional 4,791 shares in the last quarter. Prudential Financial Inc. boosted its stake in Momenta Pharmaceuticals by 1.9% in the first quarter. Prudential Financial Inc. now owns 147,062 shares of the biotechnology company’s stock valued at $1,359,000 after buying an additional 2,700 shares in the last quarter. Swiss National Bank boosted its stake in Momenta Pharmaceuticals by 2.1% in the second quarter. Swiss National Bank now owns 113,700 shares of the biotechnology company’s stock valued at $1,228,000 after buying an additional 2,300 shares in the last quarter. Finally, BNP Paribas Arbitrage SA boosted its stake in Momenta Pharmaceuticals by 115.4% in the second quarter. BNP Paribas Arbitrage SA now owns 19,816 shares of the biotechnology company’s stock valued at $214,000 after buying an additional 10,617 shares in the last quarter. 81.62% of the stock is owned by institutional investors and hedge funds.

About Momenta Pharmaceuticals

Related posts

Leave a Comment